Aligos Therapeutics Stock (NASDAQ:ALGS)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$18.50

52W Range

$6.76 - $30.00

50D Avg

$10.40

200D Avg

$15.32

Market Cap

$63.05M

Avg Vol (3M)

$214.76K

Beta

2.12

Div Yield

-

ALGS Company Profile


Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

68

IPO Date

Oct 16, 2020

Website

ALGS Performance


ALGS Financial Summary


Dec 23Dec 22Dec 21
Revenue$15.53M$13.91M$4.36M
Operating Income$-87.43M$-97.58M$-128.32M
Net Income$-87.68M$-96.05M$-128.33M
EBITDA$-84.36M$-97.58M$-128.32M
Basic EPS$-1.36$-2.25$-3.22
Diluted EPS$-1.36$-2.25$-3.22

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
NUVBNuvation Bio Inc.
ACHLAchilles Therapeutics plc
NXTCNextCure, Inc.
CTMXCytomX Therapeutics, Inc.
SPROSpero Therapeutics, Inc.
ASMBAssembly Biosciences, Inc.
NLTXNeurogene Inc.
TILInstil Bio, Inc.